Metin Kurtoglu
Equibles does not estimate personal net worth.
Get an email with a short summary when Cartesian Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get RNAC alertsAbout Metin Kurtoglu
Metin Kurtoglu is recorded as COO at Cartesian Therapeutics, Inc. (RNAC). The newest filing on record that lists Metin Kurtoglu as COO at Cartesian Therapeutics, Inc. (RNAC) is dated February 14, 2024. Cartesian Therapeutics, Inc. reported in an 8-K filed April 29, 2025 that Metin Kurtoglu was terminated as Chief Technology Officer, effective May 1, 2025. Cartesian Therapeutics, Inc. reported in an 8-K filed November 13, 2023 that Metin Kurtoglu was appointed Chief Operating Officer. Cartesian Therapeutics, Inc. reported in an 8-K filed November 13, 2023 that Metin Kurtoglu was appointed Chief Operating Officer, effective November 13, 2023. The proxy statement of Cartesian Therapeutics, Inc. reports total compensation of $2,474,034 for Metin Kurtoglu in fiscal 2025, including a base salary of $163,494. Disclosed compensation is on record for 4 fiscal years. Cartesian Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Cartesian Therapeutics, Inc. includes Carsten Brunn (CEO and Board Member), Carsten Brunn, Ph.D. (Chairman), Blaine Davis (CFO and Chief Accounting Officer) and 7 others.
“Dr. Kurtoglu’s employment with the Company will end effective May 1, 2025, and pursuant to the Consulting Agreement, Dr. Kurtoglu will serve as a consultant to the Company for the term May 1, 2025 to April 30, 2026.”
“The combined company will be led by Selecta's Chief Executive Officer, Carsten Brunn, Ph.D., and current Chief Financial Officer, Blaine Davis, as well as several members of the legacy Cartesian team, including Metin Kurtoglu, M.D., Ph.D., as Chief Operating Officer, Milos Miljkovic, M.D., as Chief Medical Officer, Chris Jewell, Ph.D., as Chief Scientific Officer, and Emily English, Ph.D., as Vice President of Quality.”
Affiliation history
-
Current
Start not stated–present
Last confirmed February 14, 2024
-
Start not stated–2025-05-01
Company network
Leadership on record at Cartesian Therapeutics, Inc.
- Carsten Brunn CEO, Board Member
- Carsten Brunn, Ph.D. Chairman
- Blaine Davis CFO, Chief Accounting Officer
- Kevin Tan CFO
- Metin Kurtoglu, M.D., Ph.D. COO
- June Seymour Chief Accounting Officer
- Adrian Bot Board Member
- Adrian Bot, M.D., Ph.D. Board Member
- Carrie S. Cox Board Member
- Kemal Malik Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Cartesian Therapeutics, Inc. (RNAC) | M.D., Ph.D. Former Chief Technology Officer | $163,494 | $2,474,034 |
| 2024 | Cartesian Therapeutics, Inc. (RNAC) | M.D., Ph.D. Chief Technology Officer | $431,539 | $2,713,064 |
| 2023 | Cartesian Therapeutics, Inc. (RNAC) | M.D., Ph.D. Chief Technology Officer | $50,313 | $71,243 |
| 2022 | Cartesian Therapeutics, Inc. (RNAC) | M.D., Ph.D. Chief Technology Officer | — | — |